# 21 C.F.R. § 314.65 (2026): Withdrawal by the applicant of an unapproved application

> Federal · Regulations · In force

URL: https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_65

## Section

- **Citation:** 21 C.F.R. § 314.65 (2026)
- **Heading:** Withdrawal by the applicant of an unapproved application
- **Jurisdiction:** Federal
- **Kind:** Regulations
- **Status:** In force
- **Text as of:** September 30, 2026
- **Source:** Compiled text
- **Location:** Title 21 CFR: Food and Drugs / Chapter I / Part 314 / Subpart B / § 314.65: § 314.65   Withdrawal by the applicant of an unapproved application.

## Text

An applicant may at any time withdraw an application that is not yet approved by notifying the Food and Drug Administration in writing. If, by the time it receives such notice, the agency has identified any deficiencies in the application, we will list such deficiencies in the letter we send the applicant acknowledging the withdrawal. A decision to withdraw the application is without prejudice to refiling. The agency will retain the application and will provide a copy to the applicant on request under the fee schedule in § 20.45 of FDA's public information regulations. [50 FR 7493, Feb. 22, 1985, as amended at 68 FR 25287, May 12, 2003; 73 FR 39609, July 10, 2008]

## Nearby sections

- [21 C.F.R. § 314.50 (2026) Content and format of an NDA.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_50.md)
- [21 C.F.R. § 314.52 (2026) § 314.52   Notice of certification of invalidity, unenforceability, or noninfringement of a patent.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_52.md)
- [21 C.F.R. § 314.53 (2026) § 314.53   Submission of patent information.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_53.md)
- [21 C.F.R. § 314.54 (2026) § 314.54   Procedure for submission of a 505(b)(2) application requiring investigations for approval of a new indication for, or other change from, a listed drug.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_54.md)
- [21 C.F.R. § 314.55 (2026) § 314.55   Pediatric use information.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_55.md)
- [21 C.F.R. § 314.56 (2026) § 314.56   Nonprescription drug product with an additional condition for nonprescription use (ACNU).](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_56.md)
- [21 C.F.R. § 314.60 (2026) § 314.60   Amendments to an unapproved NDA, supplement, or resubmission.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_60.md)
- [21 C.F.R. § 314.65 (2026) § 314.65   Withdrawal by the applicant of an unapproved application.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_65.md)
- [21 C.F.R. § 314.70 (2026) § 314.70   Supplements and other changes to an approved NDA.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_70.md)
- [21 C.F.R. § 314.71 (2026) § 314.71   Procedures for submission of a supplement to an approved application.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_71.md)
- [21 C.F.R. § 314.72 (2026) § 314.72   Change in ownership of an application.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_72.md)
- [21 C.F.R. § 314.80 (2026) § 314.80   Postmarketing reporting of adverse drug experiences.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_80.md)
- [21 C.F.R. § 314.81 (2026) Other postmarketing reports.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_81.md)
- [21 C.F.R. § 314.90 (2026) § 314.90   Waivers.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_90.md)

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_65. Check the current official text before relying on it. Not legal advice.
